Level Bio (LEVBIO.ST)

Executive Summary

Level Bio is a Swedish life science holding company based in Uppsala, focused on building a Nordic diagnostics and proteomics group. The company operates an integrated business model through its subsidiaries: CyberGene (product development and manufacturing) and Techtum Lab (distribution of diagnostic solutions). This vertical integration allows Level Bio to control the entire value chain from R&D to market access, targeting niche opportunities in molecular diagnostics and proteomics. Founded in 2016 and listed on the Stockholm Stock Exchange (ticker: LEVBIO.ST), the company has a market valuation of approximately $22 million and 68.4 million shares outstanding. Despite its small size, Level Bio leverages its Nordic base to serve a growing demand for precision diagnostics in Europe and beyond. Level Bio's strategy combines organic growth with potential acquisitions to expand its product portfolio and geographic reach. The company's subsidiaries have developed proprietary assays and instruments for protein analysis and disease detection, positioning it in segments such as infectious disease testing and personalized medicine. While financial details are limited, Level Bio's holding structure mitigates risk by diversifying revenue streams across development and distribution. Key near-term drivers include the commercial rollout of new diagnostic kits and expanding distribution partnerships. However, the company faces competition from larger diagnostics players and requires consistent funding to scale operations. Overall, Level Bio represents a small-cap opportunity in the Nordic life sciences space with potential for growth driven by its integrated model and niche focus.

Upcoming Catalysts (preview)

• Q3 2026Launch of New Diagnostic Product from CyberGene60% success
• Q4 2026Expansion of Distribution Agreement with Techtum Lab70% success
• TBDAnnouncement of Strategic Partnership or Acquisition50% success